Granules India Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| GRANULES.NS | IPCALAB.NS | IOLCP.NS | RPGLIFE.NS | MOREPENLAB.NS | INDSWFTLAB.BO | |
|---|---|---|---|---|---|---|
| Market cap | 216.71B | 494.62B | 55.50B | 42.93B | 53.21B | 31.50B |
| P/E (TTM) | 27.8 | 37.8 | 27.3 | 38.7 | 28.3 | 37.0 |
| Forward P/E | 20.7 | 27.7 | 17.5 | 27.6 | — | — |
| Price/book | 3.0 | 6.1 | 2.9 | 7.1 | 3.9 | 2.1 |
| Dividend yield | 0.22% | 0.30% | 0.54% | 0.92% | 0.20% | — |
| 1-year change | +43.88% | +51.13% | +102.86% | +6.05% | +113.46% | +268.15% |
| Today | −0.02% | −1.14% | +2.89% | −0.11% | −4.17% | −4.09% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All GRANULES.NS news ›Informist Media - Earnings Outlook: New product formulation operations to lift Granules India Q2 earnings
Informist, Saturday, Oct. 24, 2026 HYDERABAD – Granules India Ltd. is expected to report healthy growth in the September quarter, led by new product launches in its key business segments, according to analysts. The pharmaceutical company's…
Granules India Share Price Rise Streak: price, valuation
SUMMARY Granules India Ltd. Share Price Rise Streak is in its second straight session, with the latest traded price at Rs 831.55, up 2.29%, and market capitalisation at Rs 22,039.25 Cr. Granules India Ltd. (GRANULES) rose to Rs 831.55 from…
Granules India Files Paragraph IV for Ruxolitinib ER Tablets, Eyes Potential 180-Day US Exclusivity
Hyderabad: Granules India Limited has submitted a Paragraph IV certification for its Abbreviated New Drug Application (ANDA) for Ruxolitinib Extended-Release Tablets with respect to applicable patents listed in the US Food and Drug…
Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets
The Hyderabad-based company has provided the required notice to the relevant parties in accordance with applicable US regulatory requirements. If confirmed by the FDA and all applicable statutory and regulatory requirements are satisfied,…
Granules India’s ₹2,000 Crore Bet Could Reshape Hyderabad Pharma
Granules India Investment: ₹2,000 Crore Hyderabad Plan Urban Acres Granules India’s ₹2,000 Crore Bet Could Reshape Hyderabad Pharma Granules India’s plan to invest about ₹2,000 crore over the next three to four years is more than a…
Buy Granules India; target of Rs 1010: Choice Institutional Equities
TradingView Buy Granules India; target of Rs 1010: Choice Institutional Equities Choice Institutional Equities's report on Granules India Controlled Substances at Scale, Complex Generics and Oncology Next, Peptides Long Dated In
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- thehindubusinessline.com2
- businessupturn.com1
- cnbctv18.com1
- informistmedia.com1
- investmentguruindia.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.